BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.
加利福尼亚州帕洛阿尔托，2025年1月8日（环球新闻通讯社）-- BridgeBio Pharma, Inc.（纳斯达克：BBIO）（“BridgeBio”或“公司”），是一家专注于遗传疾病的新型生物制药公司，今天宣布其联合创始人兼首席执行官Neil Kumar博士将于1月13日星期一上午7:30在加州旧金山举行的第43届摩根大通医疗健康会议上进行演讲。
To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
要访问BridgeBio演示的直播网络研讨会，请访问BridgeBio网站投资者部分中的“活动与演示”页面。事件结束后，网络研讨会的回放将在BridgeBio网站上提供30天。
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
关于BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.（BridgeBio）是一家新型生物制药公司，成立的目的是发现、创造、测试和提供变革性药物，以治疗遭受遗传疾病的患者。BridgeBio的开发项目管道从早期科学到爱文思控股临床试验不等。BridgeBio成立于2015年，其团队由经验丰富的药物发现者、开发者和创新者组成，致力于将遗传医学的进步尽快应用于帮助患者。有关更多信息，请访问bridgebio.com，并在LinkedIn、Twitter和Facebook上关注我们。
BridgeBio Media Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
BridgeBio媒体联系方式：
维克拉姆·巴利
contact@bridgebio.com
(650)-789-8220
